{"id":"NCT00720941","sponsor":"Novartis Pharmaceuticals","briefTitle":"Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma","officialTitle":"Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08-14","primaryCompletion":"2012-05-21","completion":"2021-03-24","firstPosted":"2008-07-23","resultsPosted":"2013-06-17","lastUpdate":"2025-03-30"},"enrollment":1110,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Renal Cell"],"interventions":[{"type":"DRUG","name":"Pazopanib","otherNames":["GW786034"]},{"type":"DRUG","name":"Sunitinib","otherNames":[]}],"arms":[{"label":"Sunitinib","type":"ACTIVE_COMPARATOR"},{"label":"Pazopanib","type":"EXPERIMENTAL"}],"summary":"This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"From randomization until the earliest date of disease progression or date of death from any cause, assessed up to approximately 39 months","effectByArm":[{"arm":"Pazopanib 800 mg","deltaMin":8.4,"sd":null},{"arm":"Sunitinib 50 mg","deltaMin":9.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":21},"locations":{"siteCount":227,"countries":["United States","Australia","Canada","China","Germany","Ireland","Italy","Japan","Netherlands","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["37146227","32171288","31601514","29788981","29654533","27000445","26702763","26685869","26457466","23964934"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":242,"n":554},"commonTop":["Diarrhoea","Fatigue","Nausea","Hypertension","Palmar-plantar erythrodysaesthesia syndrome"]}}